Leon van Hout, Alessia D Borgo, Nienke Grun, Maaike Schuur, Martijn P G Broen, Bart A Westerman, Imke Bartelink, William Peter Vandertop, Birgit I Lissenberg-Witte, Mathilde C M Kouwenhoven
{"title":"替莫唑胺引起的严重血小板减少症与胶质母细胞瘤患者的医疗保健利用率增加有关，并且不成比例地影响女性患者。","authors":"Leon van Hout, Alessia D Borgo, Nienke Grun, Maaike Schuur, Martijn P G Broen, Bart A Westerman, Imke Bartelink, William Peter Vandertop, Birgit I Lissenberg-Witte, Mathilde C M Kouwenhoven","doi":"10.1093/nop/npaf013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thrombocytopenia is a major temozolomide-induced adverse event during the standard treatment of glioblastoma. Consequently, platelet transfusions and treatment modifications may impact quality of life and long-term treatment outcomes. Understanding the impact of thrombocytopenia on healthcare utilization is crucial to mitigate the need for healthcare resources in glioblastoma patients. Here, we assess the influence of thrombocytopenia-related healthcare among patients diagnosed with glioblastoma.</p><p><strong>Methods: </strong>We retrospectively collected patient information treated at the Brain Tumor Center Amsterdam between 2008 and 2021. The occurrence of thrombocytopenia, patient demographics, treatment details, and healthcare utilization data were gathered from patients who received standard glioblastoma treatment. Associations between temporal severity of thrombocytopenia as categorized by the Common Terminology Criteria for Adverse Events, patient characteristics, and healthcare utilization were analyzed using Generalized Linear Mixed Models.</p><p><strong>Results: </strong>We included 206 patients with a median age of 58 years, 35.9% were female and we found that thrombocytopenia (any grade) occurred in 61.1% of patients. The occurrence of thrombocytopenia during CRT was associated with increased healthcare utilization and was largest in females who developed grade 4 thrombocytopenia compared to those who did not develop thrombocytopenia (OR = 5.9, <i>P</i> < .001 in females vs OR = 4.4, <i>P</i> < .001 in males). Grade 4 thrombocytopenia was also associated with heightened healthcare utilization during the adjuvant phase (OR = 7.6, <i>P</i> < .001), and was comparable between sexes.</p><p><strong>Conclusions: </strong>Severe thrombocytopenia during glioblastoma treatment is linked to increased healthcare utilization, disproportionally impacting females. These data suggest that prevention and early management of thrombocytopenia can reduce healthcare utilization in patients with glioblastoma.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"678-690"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349765/pdf/","citationCount":"0","resultStr":"{\"title\":\"Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patients.\",\"authors\":\"Leon van Hout, Alessia D Borgo, Nienke Grun, Maaike Schuur, Martijn P G Broen, Bart A Westerman, Imke Bartelink, William Peter Vandertop, Birgit I Lissenberg-Witte, Mathilde C M Kouwenhoven\",\"doi\":\"10.1093/nop/npaf013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Thrombocytopenia is a major temozolomide-induced adverse event during the standard treatment of glioblastoma. Consequently, platelet transfusions and treatment modifications may impact quality of life and long-term treatment outcomes. Understanding the impact of thrombocytopenia on healthcare utilization is crucial to mitigate the need for healthcare resources in glioblastoma patients. Here, we assess the influence of thrombocytopenia-related healthcare among patients diagnosed with glioblastoma.</p><p><strong>Methods: </strong>We retrospectively collected patient information treated at the Brain Tumor Center Amsterdam between 2008 and 2021. The occurrence of thrombocytopenia, patient demographics, treatment details, and healthcare utilization data were gathered from patients who received standard glioblastoma treatment. Associations between temporal severity of thrombocytopenia as categorized by the Common Terminology Criteria for Adverse Events, patient characteristics, and healthcare utilization were analyzed using Generalized Linear Mixed Models.</p><p><strong>Results: </strong>We included 206 patients with a median age of 58 years, 35.9% were female and we found that thrombocytopenia (any grade) occurred in 61.1% of patients. The occurrence of thrombocytopenia during CRT was associated with increased healthcare utilization and was largest in females who developed grade 4 thrombocytopenia compared to those who did not develop thrombocytopenia (OR = 5.9, <i>P</i> < .001 in females vs OR = 4.4, <i>P</i> < .001 in males). Grade 4 thrombocytopenia was also associated with heightened healthcare utilization during the adjuvant phase (OR = 7.6, <i>P</i> < .001), and was comparable between sexes.</p><p><strong>Conclusions: </strong>Severe thrombocytopenia during glioblastoma treatment is linked to increased healthcare utilization, disproportionally impacting females. These data suggest that prevention and early management of thrombocytopenia can reduce healthcare utilization in patients with glioblastoma.</p>\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":\"12 4\",\"pages\":\"678-690\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349765/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npaf013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npaf013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：血小板减少症是替莫唑胺在胶质母细胞瘤标准治疗中引起的主要不良事件。因此，血小板输注和治疗改变可能影响生活质量和长期治疗结果。了解血小板减少症对医疗保健利用的影响对于减轻胶质母细胞瘤患者对医疗保健资源的需求至关重要。在这里，我们评估与血小板减少相关的保健对胶质母细胞瘤患者的影响。方法：回顾性收集2008年至2021年间在阿姆斯特丹脑肿瘤中心接受治疗的患者信息。从接受标准胶质母细胞瘤治疗的患者中收集血小板减少的发生率、患者人口统计学、治疗细节和医疗保健利用数据。根据不良事件的通用术语标准分类的血小板减少症的时间严重程度、患者特征和医疗保健利用之间的关联使用广义线性混合模型进行分析。结果：我们纳入206例患者，中位年龄为58岁，35.9%为女性，我们发现61.1%的患者发生血小板减少（任何级别）。CRT期间血小板减少的发生与医疗保健利用的增加有关，与未发生血小板减少的女性相比，发生4级血小板减少的女性最多（OR = 5.9, P P P P）。结论：胶质母细胞瘤治疗期间严重血小板减少与医疗保健利用的增加有关，对女性的影响不成比例。这些数据表明，预防和早期处理血小板减少症可以减少胶质母细胞瘤患者的医疗保健利用率。
Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patients.
Background: Thrombocytopenia is a major temozolomide-induced adverse event during the standard treatment of glioblastoma. Consequently, platelet transfusions and treatment modifications may impact quality of life and long-term treatment outcomes. Understanding the impact of thrombocytopenia on healthcare utilization is crucial to mitigate the need for healthcare resources in glioblastoma patients. Here, we assess the influence of thrombocytopenia-related healthcare among patients diagnosed with glioblastoma.
Methods: We retrospectively collected patient information treated at the Brain Tumor Center Amsterdam between 2008 and 2021. The occurrence of thrombocytopenia, patient demographics, treatment details, and healthcare utilization data were gathered from patients who received standard glioblastoma treatment. Associations between temporal severity of thrombocytopenia as categorized by the Common Terminology Criteria for Adverse Events, patient characteristics, and healthcare utilization were analyzed using Generalized Linear Mixed Models.
Results: We included 206 patients with a median age of 58 years, 35.9% were female and we found that thrombocytopenia (any grade) occurred in 61.1% of patients. The occurrence of thrombocytopenia during CRT was associated with increased healthcare utilization and was largest in females who developed grade 4 thrombocytopenia compared to those who did not develop thrombocytopenia (OR = 5.9, P < .001 in females vs OR = 4.4, P < .001 in males). Grade 4 thrombocytopenia was also associated with heightened healthcare utilization during the adjuvant phase (OR = 7.6, P < .001), and was comparable between sexes.
Conclusions: Severe thrombocytopenia during glioblastoma treatment is linked to increased healthcare utilization, disproportionally impacting females. These data suggest that prevention and early management of thrombocytopenia can reduce healthcare utilization in patients with glioblastoma.
期刊介绍：
Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
